Survivin is a negative prognostic factor in malignant pleural effusion

Area of Science:

• Oncology
• Pulmonology
• Biochemistry

Background:

• Survivin, an inhibitor of apoptosis protein, is linked to increased tumor aggressiveness.
• Survivin has been detected in both tumor tissue and pleural fluid.

Purpose of the Study:

• To investigate changes in pleural fluid survivin concentrations after talc instillation for malignant pleural effusion.
• To correlate these survivin changes with pleurodesis success and patient survival.

Main Methods:

• Studied 84 patients with malignant pleural effusion undergoing talc pleurodesis (32 breast, 25 lung cancer, 27 mesothelioma).
• Collected serial pleural fluid samples pre-thoracoscopy (baseline) and 24 hours post-procedure.

Main Results:

• Pleural fluid survivin levels significantly increased post-talc poudrage compared to baseline.
• Higher baseline survivin levels correlated with poorer pleurodesis outcomes.
• A baseline survivin cut-off of 30 pg/mL predicted pleurodesis failure (54% sensitivity, 79% specificity).
• Patients with baseline survivin ≥30 pg/mL had a median survival of 4 months vs. 13 months for those below the cut-off.

Conclusions:

• Elevated pleural fluid survivin concentrations are a valuable predictor of pleurodesis failure in malignant pleural effusion.
• Higher survivin levels are associated with significantly shorter survival in these patients.